Response assessment in non-small cell lung cancer immunotherapy: initial experiences in utilizing FDG PET/CT and the PD-1 blocker nivolumab

ConclusionsThe findings indicate that the PERCIST-based evaluation could identify progressive disease earlier. Early identification of nonresponders could lead to prevention of overtreatment and to an early switch to a  more effective therapy.

Source: Memo - Magazine of European Medical Oncology - May 28, 2019 Category: Cancer & Oncology Source Type: research